Lin Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lin Chen has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Ailing Yu
Institute of Biomedical Engineering, School of Ophthalmology & Optometry, Eye Hospital, Wenzhou Medical University, 270 Xueyuan Road, Wenzhou, 325027, PR China
1 shared publicationAntian Wang
Department of Pharmacology and Chemical Biology Collaborative Innovation Center for Clinical and Translational Science by Chinese Ministry of Education & Shanghai Shanghai Jiao Tong University School of Medicine Shanghai 200025 China
1 shared publicationBo Jin
Institute of Biomedical Engineering, School of Ophthalmology & Optometry, Eye Hospital, Wenzhou Medical University, 270 Xueyuan Road, Wenzhou, 325027, PR China
1 shared publicationChen Fan
Department of Pharmacology and Chemical Biology Collaborative Innovation Center for Clinical and Translational Science by Chinese Ministry of Education & Shanghai Shanghai Jiao Tong University School of Medicine Shanghai 200025 China
1 shared publicationChenyun Zhang
Department of Pharmacology and Chemical Biology Collaborative Innovation Center for Clinical and Translational Science by Chinese Ministry of Education & Shanghai Shanghai Jiao Tong University School of Medicine Shanghai 200025 China
1 shared publicationGan Jiang
Department of Pharmacology and Chemical Biology Collaborative Innovation Center for Clinical and Translational Science by Chinese Ministry of Education & Shanghai Shanghai Jiao Tong University School of Medicine Shanghai 200025 China
1 shared publication
Latest Publications
- 28 August 2025
- Published by Wiley in Advanced Materials
- Vol. 37 (44) , e08104
Trojan Horse‐Inspired Biomimetic Lipoprotein Nanocarrier for Noninvasive Anti‐VEGF Therapy of Ocular Fundus Neovascularization
Pathological neovascularization is a major cause of vision loss in various ischemic and inflammatory ocular fundus diseases, with current anti‐VEGF therapies requiring invasive and frequent intravitreal injections. In this study, a Trojan horse‐inspired biomimetic lipoprotein nanocarrier (A‐PA‐αCPP) is developed for noninvasive anti‐VEGF therapy via topical administration. Utilizing phosphatidic acid (PA), specifically 1,2‐dioleoyl‐sn‐glycero‐3‐phosphate (DOPA), as the sole phospholipid, the nanocarrier enables electrostatic tethering of aflibercept, with a cell‐penetrating peptide (CPP)‐functionalized apoA1 mimetic peptide (αCPP) incorporated through self‐assembly. Molecular dynamics simulations and intermolecular interaction experiments confirm effective PA–protein interactions and αCPP incorporation. The nanocarrier demonstrates high encapsulation efficiency, size uniformity, and long‐term stability. It enhances transcellular and paracellular transport by promoting cellular uptake, bypassing lysosomal degradation, and modulating tight junctions. When topically administered, A‐PA‐αCPP efficiently delivers to the posterior segment via corneal and conjunctival–scleral–choroidal pathways. In a laser‐induced choroidal neovascularization (CNV) mouse model, A‐PA‐αCPP eye drops show therapeutic efficacy comparable to a single intravitreal injection, while maintaining excellent ocular and systemic biocompatibility. This biomimetic platform highlights the potential of PA‐mediated protein binding in nanocarrier design, offering a promising strategy for home‐based anti‐VEGF therapy and extending the potential to other protein‐based therapeutics.
- 28 August 2025
- Published by Wiley in Advanced Materials
- Vol. 37 (44) , e08104
Trojan Horse‐Inspired Biomimetic Lipoprotein Nanocarrier for Noninvasive Anti‐VEGF Therapy of Ocular Fundus Neovascularization
Pathological neovascularization is a major cause of vision loss in various ischemic and inflammatory ocular fundus diseases, with current anti‐VEGF therapies requiring invasive and frequent intravitreal injections. In this study, a Trojan horse‐inspired biomimetic lipoprotein nanocarrier (A‐PA‐αCPP) is developed for noninvasive anti‐VEGF therapy via topical administration. Utilizing phosphatidic acid (PA), specifically 1,2‐dioleoyl‐sn‐glycero‐3‐phosphate (DOPA), as the sole phospholipid, the nanocarrier enables electrostatic tethering of aflibercept, with a cell‐penetrating peptide (CPP)‐functionalized apoA1 mimetic peptide (αCPP) incorporated through self‐assembly. Molecular dynamics simulations and intermolecular interaction experiments confirm effective PA–protein interactions and αCPP incorporation. The nanocarrier demonstrates high encapsulation efficiency, size uniformity, and long‐term stability. It enhances transcellular and paracellular transport by promoting cellular uptake, bypassing lysosomal degradation, and modulating tight junctions. When topically administered, A‐PA‐αCPP efficiently delivers to the posterior segment via corneal and conjunctival–scleral–choroidal pathways. In a laser‐induced choroidal neovascularization (CNV) mouse model, A‐PA‐αCPP eye drops show therapeutic efficacy comparable to a single intravitreal injection, while maintaining excellent ocular and systemic biocompatibility. This biomimetic platform highlights the potential of PA‐mediated protein binding in nanocarrier design, offering a promising strategy for home‐based anti‐VEGF therapy and extending the potential to other protein‐based therapeutics.
- Open Access
- 10 September 2021
- Published by KEAI Publishing in Bioactive Materials
- Vol. 10, 420-429
Drug-peptide supramolecular hydrogel boosting transcorneal permeability and pharmacological activity via ligand-receptor interaction
Boosting transcorneal permeability and pharmacological activity of drug poses a great challenge in the field of ocular drug delivery. In the present study, we propose a drug-peptide supramolecular hydrogel based on anti-inflammatory drug, dexamethasone (Dex), and Arg-Gly-Asp (RGD) motif for boosting transcorneal permeability and pharmacological activity via the ligand-receptor interaction. The drug-peptide (Dex-SA-RGD/RGE) supramolecular hydrogel comprised of uniform nanotube architecture formed spontaneously in phosphate buffered saline (PBS, pH = 7.4) without external stimuli. Upon storage at 4 °C, 25 °C, and 37 °C for 70 days, Dex-SA-RGD in hydrogel did not undergo significant hydrolysis, suggesting great long-term stability. In comparison to Dex-SA-RGE, Dex-SA-RGD exhibited a more potent in vitro anti-inflammatory efficacy in lipopolysaccharide (LPS)-activated RAW 264.7 macrophages via the inhibition of nuclear factor кB (NF-κB) signal pathway. More importantly, using drug-peptide supramolecular hydrogel labeled with 7-nitro-2,1,3-benzoxadiazole (NBD), the Dex-SA-K(NBD)RGD showed increased performance in terms of integrin targeting and cellular uptake compared to Dex-SA-K(NBD)RGE, as revealed by cellular uptake assay. On topical instillation in rabbit's eye, the proposed Dex-SA-K(NBD)RGD could effectively enhance the transcorneal distribution and permeability with respect to the Dex-SA-K(NBD)RGE. Overall, our findings demonstrate the performance of the ligand-receptor interaction for boosting transcorneal permeability and pharmacological activity of drug.
- 10 September 2021
- Published by KEAI Publishing in Bioactive Materials
- Vol. 10, 420-429
Open AccessDrug-peptide supramolecular hydrogel boosting transcorneal permeability and pharmacological activity via ligand-receptor interaction
Boosting transcorneal permeability and pharmacological activity of drug poses a great challenge in the field of ocular drug delivery. In the present study, we propose a drug-peptide supramolecular hydrogel based on anti-inflammatory drug, dexamethasone (Dex), and Arg-Gly-Asp (RGD) motif for boosting transcorneal permeability and pharmacological activity via the ligand-receptor interaction. The drug-peptide (Dex-SA-RGD/RGE) supramolecular hydrogel comprised of uniform nanotube architecture formed spontaneously in phosphate buffered saline (PBS, pH = 7.4) without external stimuli. Upon storage at 4 °C, 25 °C, and 37 °C for 70 days, Dex-SA-RGD in hydrogel did not undergo significant hydrolysis, suggesting great long-term stability. In comparison to Dex-SA-RGE, Dex-SA-RGD exhibited a more potent in vitro anti-inflammatory efficacy in lipopolysaccharide (LPS)-activated RAW 264.7 macrophages via the inhibition of nuclear factor кB (NF-κB) signal pathway. More importantly, using drug-peptide supramolecular hydrogel labeled with 7-nitro-2,1,3-benzoxadiazole (NBD), the Dex-SA-K(NBD)RGD showed increased performance in terms of integrin targeting and cellular uptake compared to Dex-SA-K(NBD)RGE, as revealed by cellular uptake assay. On topical instillation in rabbit's eye, the proposed Dex-SA-K(NBD)RGD could effectively enhance the transcorneal distribution and permeability with respect to the Dex-SA-K(NBD)RGE. Overall, our findings demonstrate the performance of the ligand-receptor interaction for boosting transcorneal permeability and pharmacological activity of drug.